Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)

Part of paid clinical trials in Cleveland, Ohio.

Sponsor
University Hospitals Cleveland Medical Center
Study ID
NCT02824471
Status
Recruiting
Apply to this trial

Conditions

Eligibility Criteria

Sex
ALL
Age
12 Years - N/A
Healthy Volunteers
Accepted

Interventions

  • SCD Group — OTHER
    No Intervention. Use of discard blood/tissue

Study Details

'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell membrane properties, shape, and density, and subsequent critical changes in inflammatory cell and endothelial cell function. Our goal is to understand the impact of CMA abnormalities in SCD, by interrogating a number of recognized interactions in a range of clinical phenotypes. To date, correlative studies in SCD, by us and others, have range between clinical reports, based on tests, interventions, and chart review of individuals or groups of individuals and, at the other extreme, identification of functional gene polymorphisms based on population studies. The investigators wish to augment these studies through a systematic examination of cellular membrane properties and activation status. Of hematologic disorders, SCD may be unusually susceptible to such an examination.

Key Dates

Start date
Oct 31, 2014
Status verified
Aug 2025
Primary completion
May 31, 2028
Completion
May 31, 2028

Study Design

Enrollment
100 participants (estimated)

Arms

  • Arm: Minor SCD Group, Ages 12-17
    No Intervention. Use of discarded blood/tissue only
  • Arm: Adult SCD. Ages 18+
    No Intervention. Use of discarded blood/tissue only

Primary Outcome Measure

Develop an SCD Biochip with which to examine key cellular properties and interactions, including RBC and WBC cellular, adhesive, and inflammatory properties, and circulating endothelial and hematopoietic precursor cell characteristics. [ Time Frame: 2 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University Hospitals Case Medical CenterClevelandOhio44106
Amma Owusu-Ansah, MD
[email protected]
216-844-3345
Umut A Gurkan, Ph.D.
[email protected]
216-368-6447
Amma Owusu-Ansah, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Cleveland, OH

By condition
Sickle cell disease
By research site
University Hospitals Case Medical Center· Cleveland, OH

Related Studies